4D Molecular Therapeutics (FDMT) Cash & Current Investments (2019 - 2026)

4D Molecular Therapeutics (FDMT) has 8 years of Cash & Current Investments data on file, last reported at $390.9 million in Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 21.61% year-over-year to $390.9 million in Q1 2026; TTM through Mar 2026 was $390.9 million, a 21.61% increase from a year earlier, with the FY2025 full-year figure at $402.7 million, down 5.23% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $390.9 million, down from $402.7 million in the prior quarter.
• Over the last five years, Cash & Current Investments for FDMT reached as high as $541.9 million in Q2 2024 and fell as low as $200.5 million in Q1 2023.
• Historically, Cash & Current Investments has averaged $337.9 million across 5 years, with a median of $310.3 million in 2023.
• Across the five-year window, Cash & Current Investments surged 162.36% in 2024 and sank 45.89% in 2025, its largest moves.
• Year by year, Cash & Current Investments stood at $213.6 million in 2022, then surged by 34.97% to $288.2 million in 2023, then jumped by 47.41% to $424.9 million in 2024, then dropped by 5.23% to $402.7 million in 2025, then dropped by 2.92% to $390.9 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $390.9 million in Q1 2026, $402.7 million in Q4 2025, and $305.1 million in Q3 2025.